Nasdaq

Madrigal Pharmaceuticals Reports Preliminary 2024 Net Sales and Patient Milestones for Rezdiffra™

Madrigal Pharmaceuticals provided an update on its financial performance, revealing preliminary fourth-quarter and full-year 2024 net sales for Rezdiffra™ (resmetirom) projected between $100 million ...
Seeking Alpha

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

CONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...
Seeking Alpha

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

CONSHOHOCKEN, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH) ...
Hosted on MSN

Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a pivotal year highlighted by the FDA approval and successful launch of Rezdiffra ...
clinicaladvisor.com

Rezdiffra for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic ...